Detalles de la búsqueda
1.
Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain.
Contemp Clin Trials
; 121: 106900, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36038003
2.
Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy.
Alzheimers Dement (N Y)
; 3(3): 339-347, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29067341
3.
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.
J Alzheimers Dis
; 53(2): 535-46, 2016 05 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27163805
4.
Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.
Alzheimers Res Ther
; 8(1): 24, 2016 Jun 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-27334799
5.
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials.
Alzheimers Dement (N Y)
; 1(2): 141-149, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29854934
6.
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab.
Alzheimers Dement (N Y)
; 1(3): 157-169, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29854935
7.
Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease.
Arch Neurol
; 60(8): 1143-8, 2003 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12925373
8.
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease.
Clin Neuropharmacol
; 36(1): 8-13, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23334069
9.
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.
Ann Neurol
; 51(2): 145-55, 2002 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-11835370
Resultados
1 -
9
de 9
1
Próxima >
>>